Edwards Lifesciences Corp. CEO Michael A. Mussallem Sells 29,500 Shares (EW)
Edwards Lifesciences Corp. (NYSE:EW) CEO Michael A. Mussallem sold 29,500 shares of Edwards Lifesciences Corp. stock in a transaction dated Thursday, January 9th. The shares were sold at an average price of $67.04, for a total value of $1,977,680.00. Following the completion of the transaction, the chief executive officer now directly owns 263,850 shares in the company, valued at approximately $17,688,504. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Edwards Lifesciences Corp. (NYSE:EW) traded up 0.38% during mid-day trading on Monday, hitting $68.74. 1,014,329 shares of the company’s stock traded hands. Edwards Lifesciences Corp. has a 1-year low of $60.62 and a 1-year high of $94.61. The stock has a 50-day moving average of $65.00 and a 200-day moving average of $68.76. The company has a market cap of $7.521 billion and a price-to-earnings ratio of 19.47.
Edwards Lifesciences Corp. (NYSE:EW) last posted its quarterly earnings results on Monday, October 28th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.02. The company had revenue of $496.00 million for the quarter, compared to the consensus estimate of $490.96 million. During the same quarter in the previous year, the company posted $0.58 earnings per share. The company’s revenue for the quarter was up 10.6% on a year-over-year basis. Analysts expect that Edwards Lifesciences Corp. will post $3.05 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Barclays cut their price target on shares of Edwards Lifesciences Corp. from $68.00 to $64.00 in a research note to investors on Tuesday, December 10th. They now have an “equal weight” rating on the stock. Separately, analysts at Citigroup Inc. reiterated a “buy” rating on shares of Edwards Lifesciences Corp. in a research note to investors on Tuesday, December 10th. They now have a $72.00 price target on the stock, down previously from $75.00. Finally, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Edwards Lifesciences Corp. in a research note to investors on Tuesday, December 10th. They now have a $74.00 price target on the stock, down previously from $76.00. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $73.88.
Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.